To Evaluate the Long-term Persistence of Rotavirus Antibody Responses in Children Previously Vaccinated With a 3-Dose Infant Schedule or 4-Dose Neonatal Schedule with ROTAVAC-20 C or ROTAVAC 5D (BBIL/ROTAVAC/III/2018). - Rotavac@Birth phase 3 extension study
Latest Information Update: 27 Nov 2020
At a glance
- Drugs ORV 116E (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- Acronyms Rotavac@Birth phase 3 extension study
- Sponsors Bharat Biotech
- 27 Nov 2020 New trial record